A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, With or Without Simeprevir, in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Infection With or Without Compensated Child Pugh A Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs AL 335 (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Alios BioPharma
- 14 Aug 2017 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.
- 14 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 30 Dec 2017.
- 22 Apr 2017 According to an Achillion Pharmaceuticals media release, this study will support global development of JNJ-4178.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History